Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P123 is a human processed pseudogene derived from the ribosomal protein L21 gene family. Pseudogenes are genomic DNA sequences similar to known genes but generally non-functional due to accumulation of mutations or lack of regulatory elements. RPL21P123 does not encode a functional protein and is not considered a molecular target for drugs or therapeutic intervention. Its name reflects its relationship to the ribosomal protein L21, which is a component of the 60S ribosomal subunit involved in cellular protein synthesis. There is no evidence of direct biological function, disease association, or relevance as a biomarker or pharmacological target for RPL21P123. Any information regarding function or drug interaction refers instead to the parent gene RPL21.
None (no known mechanism, as not a druggable target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 123 (RPL21P123).